Acadia Pharmaceuticals ACAD Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's operating lease right-of-use assets in other assets?
- Acadia Pharmaceuticals (ACAD) reported operating lease right-of-use assets in other assets of $46.27M in Q1 2026.
- How has Acadia Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Acadia Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 8.6% year-over-year, from $50.61M to $46.27M.
- What is the long-term trend for Acadia Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 0.0% compound annual growth rate (CAGR), from $47.28M to $47.35M.